This data confirms that semaglutide stands apart as the only available GLP-1-based medication with proven cardiovascular benefits for people living with obesity and cardiovascular disease, without diabetes. Additionally, in all treated people, regardless of any gaps in their treatment, people treated with semaglutide experienced fewer events of heart attack, stroke and cardiovascular-related death than people treated with tirzepatide
Just as importantly, you deserve to feel confident while on your journey
Experiment with timing to find what works for your schedule and relationship patterns
Helpful very professional and friendly
As Pharmacy Benefit Management (PBM) costs face continued policy pressure, its unsurprising that a growing majority of employers are exploring cash-pay access models, like pharmacies and weight loss programs, to control spend and improve predictability